Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma

@inproceedings{Decock2016MethylCpGbindingDS,
  title={Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma},
  author={Anneleen Decock and Mat{\'e} Ongenaert and Robrecht Cannoodt and Kimberly Verniers and Bram de Wilde and Genevi{\'e}ve Laureys and Nadine Van Roy and Ana P. Berbegall and Julie Bienertov{\'a}-Va{\vs}ků and Nick P Bown and Nathalie Cl{\'e}ment and Valerie Combaret and Michelle Haber and Claire Hoyoux and Jayne Murray and Rosa Noguera and Gaelle Pierron and Gudrun Schleiermacher and Johannes Hubertus Schulte and Ray L. Stallings and Deborah Anne Tweddle and Katleen De Preter and Frank Speleman and Jo Vandesompele},
  booktitle={Oncotarget},
  year={2016}
}
Accurate assessment of neuroblastoma outcome prediction remains challenging. Therefore, this study aims at establishing novel prognostic tumor DNA methylation biomarkers. In total, 396 low- and high-risk primary tumors were analyzed, of which 87 were profiled using methyl-CpG-binding domain (MBD) sequencing for differential methylation analysis between prognostic patient groups. Subsequently, methylation-specific PCR (MSP) assays were developed for 78 top-ranking differentially methylated… CONTINUE READING